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Abstract
Background If patients in oncology trials receive subsequent
therapy, standard intention-to-treat (ITT) analyses may inaccu-
rately estimate the overall survival (OS) effect of the investiga-
tional product. In this context, a post-hoc analysis of the phase 3
PREVAIL study was performed with the aim to compare
enzalutamide with placebo in terms of OS, adjusting for poten-
tial confounding from switching to antineoplastic therapies that
are not part of standard metastatic castration-resistant prostate
cancer (mCRPC) treatment pathways in some jurisdictions.
Methods The PREVAIL study, which included 1717 chemo-
therapy-naïve men with mCRPC randomized to treatment
with enzalutamide 160 mg/day or placebo, was stopped after
a planned interim survival analysis revealed a benefit in favor
of enzalutamide. Data from this cutoff point were confounded
by switching from both arms and so were evaluated in terms
of OS using two switching adjustment methods: the two-stage
accelerated failure time model (two-stagemethod) and inverse
probability of censoring weights (IPCW).
Results Following adjustment for switching to nonstandard an-
tineoplastic therapies by 14.8 (129/872 patients) and 21.3% (180/
845 patients) of patients initially randomized to enzalutamide and
placebo, respectively, the two-stage and IPCW methods both
resulted in numerical reductions in the hazard ratio (HR) for
OS [HR 0.66, 95% confidence interval (CI) 0.57–0.81 and HR
0.63, 95% CI 0.52–0.75, respectively] for enzalutamide com-
pared to placebo versus the unadjusted ITT analysis (HR 0.71,
95%CI 0.60–0.84). These results suggest a slightly greater effect
of enzalutamide on OS than originally reported.
Conclusion In the PREVAIL study, switching to nonstandard
antineoplastic mCRPC therapies resulted in the ITT analysis of
primary data underestimating the benefit of enzalutamide onOS.
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1 Introduction
Treatment switching has become an important issue in the
development and approval of new drugs, particularly with
regard to oncology [1]. In oncology trials, if cancer pro-
gresses, it is common to offer patients the option of
switching from their randomized treatment to another ac-
tive therapy (Fig. 1). Although the practice of treatment
switching has the potential to affect the results of clinical
evaluations of investigational products, it is likely to be
more problematic for health technology assessment
(HTA) agencies than for licensing bodies. For the purpose
of regulatory approval, an accurate estimate of the overall
survival (OS) hazard ratio (HR) may not always be re-
quired, and in some instances a statistically significant ad-
vantage for progression-free survival (PFS) may be suffi-
cient. However, for an HTA, accurate estimates of both the
PFS and OS treatment effect are needed; therefore, treat-
ment switching is more of an issue.
Importantly, if patients switch to and benefit from an-
other active therapy, the true OS benefit associated with
the original investigational product may be inaccurately
estimated using standard intention-to-treat (ITT) method-
ology, and this in turn can affect subsequent cost-
effectiveness analyses that use OS evidence [2].
Adjustment methods are available that provide better es-
timates of true drug effects. However, economic evalua-
tions should only adjust for switching to active
postprogression therapies that are not part of the standard
treatment pathway [2]. From a pragmatic perspective,
decision-makers typically want to ascertain the effect of
including a new drug in a therapeutic regimen. If a new
treatment improves the prognosis of a patient and en-
hances their suitability for subsequent treatment lines, this
can be considered as a benefit of treatment for which
adjustments are unnecessary, provided the subsequent
treatments reflect those that would be expected in reality.
However, if patients switch to poststudy experimental or
nonstandard therapies, the survival experience observed in
the trial will not be that which would be expected in
reality; for these switches, adjustments are required to
estimate the expected impact of adding the new treatment
into the standard treatment pathway.
A range of switching adjustment methods are avail-
able, and these are generally classified as randomization
based, such as the rank-preserving structural failure time
model (RPSFTM) [3] or iterative parameter estimation
algorithm (IPE) [4]), or observational based, such as
the two-stage accelerated failure time model (two-stage
method) [5, 6] or inverse probability of censoring
weights (IPCW) [7]).
As different switching adjustment methods have varying
limitations, they are appropriate in different scenarios, and
the most adequate method depends on the characteristics of
the trial from which data are being evaluated [2].
Enzalutamide is a potent oral androgen-receptor signal-
ing inhibitor developed to treat metastatic castration-
resistant prostate cancer (mCRPC) [8]. Its clinical benefits
have been demonstrated in the phase 3, double-blind,
placebo-controlled AFFIRM and PREVAIL studies [9,
10]. Results of the AFFIRM study [9] supported the initial
approval of enzalutamide to treat mCRPC that had
progressed after chemotherapy, and those of the
PREVAIL study [10] supported extension of the
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Fig. 1 Schematic overview of possible treatment switching occurring in randomized clinical trials (RCTs) of cancer treatments
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indication to include patients who were chemotherapy
naïve [11, 12].
PREVAIL was stopped after a planned interim survival
analysis (data cutoff September 16, 2013), performed at 540
reported deaths, which revealed a benefit in favor of
enzalutamide for radiographic PFS [ITT analysis HR for
enzalutamide vs. placebo 0.19; 95% confidence interval (CI)
0.15–0.23; P < 0.001] and OS (ITT analysis HR for
enzalutamide vs. placebo 0.71; 95% CI 0.60–0.84;
P < 0.001) [10]. All patients were followed up for OS after
discontinuing study treatment. At the time of the September
2013 data cutoff, 43.8% (382/872) of patients in the
enzalutamide arm and 76% (642/845) of patients in the place-
bo arm had received subsequent antineoplastic therapy (40.3
and 70.3%, respectively, had taken subsequent antineoplastics
associated with a demonstrated survival benefit in metastatic
prostate cancer) [10].
Here we describe analyses that estimate the effects of
enzalutamide versus placebo onOS, adjusting for the potential
confounding effects of switching to antineoplastic therapies
that are not part of the standard mCRPC treatment pathway
in the UK. Although the analyses are therefore presented from
a UK perspective, where such analyses are routinely consid-
ered by the National Institute for Health and Care Excellence
(NICE) [13], adjustment analyses are becoming more com-
monly expected in other jurisdictions [1]. With due consider-
ation of standard treatment pathways in other countries, ad-
justment analyses could be tailored accordingly.
2 Methods
2.1 Study Design
This is a post-hoc analysis of OS following treatment
switching in patients enrolled in the PREVAIL study.
PREVAIL (ClinicalTrials.gov number: NCT01212991) in-
cluded 1717 chemotherapy-naïve men with mCRPC who
were randomized to receive enzalutamide 160 mg/day (n =
872) or placebo (n = 845) [10]. OS and PFS were coprimary
endpoints.
In our analysis, treatment switching was defined as the
receipt of any postbaseline antineoplastic therapy, excluding
treatment to which patients were randomized, that was not part
of the standard treatment pathway in the UK according to the
NICE clinical guideline for prostate cancer [14] and clinical
expert opinion. Nonstandard treatment comprised
enzalutamide, abiraterone, cabazitaxel, sipuleucel-T and in-
vestigational drugs, as well as other chemotherapeutic cyto-
toxic drugs (including estramustine, cyclophosphamide,
mitoxantrone, carboplatin, cisplatin and chemotherapeutics)
and noncytotoxic treatment (including cetuximab, methotrex-
ate, and thalidomide). Patients receiving such nonstandard
therapy were termed switchers. Patients receiving standard
treatment (i.e. docetaxel, hormonal treatments or
antiandrogens) or who did not receive any other antineoplastic
treatment after study drug discontinuation, were regarded to
be nonswitchers.
Various statistical methods are available to adjust survival
estimates in the presence of treatment switching [15].
Following recommendations in the NICE Decision Support
Unit Technical Support Document 16 [15], we evaluated the
characteristics of PREVAIL [9] and treatment switching
mechanism and assessed the applicability and suitability of
the different treatment switching adjustment methods. Based
on the results of this assessment, we considered two
observational-based methods, namely, the two-stage method
and the IPCW, to be the most appropriate for use in the current
analysis.
2.2 Adjustment Methods
As the two-stage and IPCWmethods have been described and
their use considered previously [5–7, 15], these are only de-
scribed briefly here. More in-depth information relating to the
application of these methods to the PREVAIL data is provided
in Electronic Supplementary Material (ESM) 1.
Both methods included the same covariates (Table 1), with
selection based on clinical expert opinion and prior knowl-
edge of the disease. Missing values for covariates were imput-
ed using either the mean for the trial population or the last
observation carried forward. Parameter estimate values and
odds ratios for the coefficients for the two-stage (Weibull
and generalized gamma applications) and IPCW methods
(September 2013 data cutoff) have been included in ESM 2–
5. HR and 95% CI data for the IPCW-adjusted Cox propor-
tional hazards model are provided in ESM 6.
2.2.1 Two-Stage Method
In general terms, the two-stage method involves estimating a
treatment effect specific to switching patients and using this
effect to derive a counterfactual dataset unaffected by
switching [5, 6]. A disease event, defined here as the treatment
discontinuation date, is used as a secondary baseline, and data
beyond this point are treated as an observational dataset. As
both the enzalutamide and placebo arms of PREVAIL includ-
ed switchers, data from the secondary baseline onward were
regarded as two separate observational datasets—one for each
randomized treatment group. Accelerated failure time models
(Weibull and generalized gamma) were fitted separately to the
two observational datasets to estimate the treatment effect as-
sociated with switching in the two randomized groups.
Acceleration factors (AFs), calculated separately for the
enzalutamide and placebo arms, were used to shrink the sur-
vival time for switchers in each group to derive the
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counterfactual survival dataset—that is, a dataset in which
survival times of switching patients were adjusted to those
times that would have been expected had switching not oc-
curred. Standard survival analyses were performed on this
dataset to estimate the treatment effect of enzalutamide versus
placebo, adjusted to account for treatment switching. The fits
of the accelerated failure time models were evaluated using
the Akaike information criterion (AIC) and Bayesian
Information Criterion (BIC), with lower values indicative of
a better statistical fit.
With the methodology involving estimation of counterfac-
tual survival times, recensoring was undertaken as recom-
mended in the literature [16]. Results without recensoring
were also assessed because recensoring can lead to bias if
the treatment effect varies over time [15].
Finally, a Cox regression model was used to estimate an
adjusted HR for enzalutamide on OS, and the 95% CI was
estimated by bootstrapping the entire adjustment process.
This two-stage method can only be used if an appropriate
secondary baseline exists, at which point there should be no
unmeasured confounders, and switching should occur
promptly after the secondary baseline to avoid time-
dependent confounding.
2.2.2 IPCW Method
The IPCWmethod as applied here involved censoring patients
at the time of treatment switch and weighting the follow-up
information for the remaining patients so that the information
accounted both for the remaining patients and for patients with
similar characteristics (both baseline and time dependent)
whose follow-up was censored [7]. A weighted Cox regres-
sion model was used to estimate an adjusted HR for OS, and a
95% CI for the HR was estimated using bootstrapping. A
weighted Kaplan–Meier curve was also obtained.
The IPCW method assumes that there are no unmeasured
confounders, with data being available for all baseline and
time-dependent prognostic factors for mortality that also pre-
dict informative censoring (switching). The method also relies
on the models for switching and survival being correctly spec-
ified. Stabilized weights are commonly used within the IPCW
method [7]. When switching proportions are very high, or if
certain patient characteristics are very strong predictors of
switching, extreme weights can be obtained. In these circum-
stances the IPCW becomes prone to error [5, 6]; to investigate
this, we analyzed the weights obtained.
3 Results
The results presented below focus on the analysis of data
obtained during the PREVAIL trial at the cutoff at which the
planned interim survival analysis, performed at 540 reported
deaths, revealed a benefit in favor of enzalutamide (September
16, 2013) [9]. However, when granting the extended indica-
tion for enzalutamide, the US Food and Drug Administration
(FDA) requested an updated analysis of the OS endpoint to be
performed that contained a minimum of the original protocol-
defined number of deaths (765); the data cutoff for this sub-
sequent analysis was June 1, 2014 [17]. Consequently, results
pertaining to the latter cutoff are also briefly considered at the
end of the Results section.
3.1 Patient Disposition and Treatment Switching
At the interim data cutoff (September 16, 2013), treatment
with the study medication was ongoing for 42.1% of patients
randomized to receive enzalutamide (367/872) and 7.2% of
those assigned to placebo (61/845) (Table 2). There was one
patient in each group who did not receive study treatment.
Thus, a total of 1287 patients discontinued the study drug, of
whommore were in the placebo arm (92.7%, 783/845) than in
the enzalutamide arm (57.8%, 504/872). The primary reason
Table 1 Covariates used in the two-stage and inverse probability of
censoring weights methods
Covariates
Baseline covariates:
Age (years, continuous)
Time since diagnosis (categorical; <5 vs. ≥5 years)
Number of bone metastases at screening (categorical; ≤5 vs. >5)
Presence of visceral disease at baseline (categorical; yes vs. no)
Type of disease progression at study entry (categorical; PSA
progression only vs. radiographic progression with or without
PSA vs. no disease progression at study entry)
Baseline EQ-5D utility index (continuous)
Baseline FACT-P total score (continuous)
Secondary baseline covariates:
ECOG Performance Status at secondary baseline (categorical;
0 vs. otherwise)
Occurrence of grade 3–5 adverse events at secondary baseline
(categorical; yes vs. no)
Occurrence of grade 3–5 adverse events prior to the secondary
baseline (categorical; yes vs. no)
Corticosteroid use at secondary baseline (categorical; yes vs. no)
PSA level at secondary baseline (continuous)
Laboratory tests: LDH level at secondary baseline (categorical;
≤240 IU/mL vs. >240 IU/mL)
EQ-5D utility index at secondary baseline (continuous)
FACT-P total score at secondary baseline (continuous)
Time to treatment discontinuation (continuous)
Disease progression (categorical; yes vs. no)
Switching indicator (yes vs. no)
ECOG Eastern Cooperative Oncology Group, FACT-P Functional
Assessment of Cancer Therapy–Prostate, LDH lactate dehydrogenase,
PSA prostate-specific antigen
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for study drug discontinuation was disease progression, re-
ported for 70.4% (355/504) and 73.7% (577/783) of
discontinuing patients in the enzalutamide and placebo arms,
respectively.
A total of 309 switchers were identified (Table 2); of these,
14.8% (129/872) and 21.3% (180/845) of patients in the
enzalutamide arm and placebo arm, respectively, received an-
tineoplastic therapies that were not part of the standard treat-
ment pathway in the UK. The most common of the nonstan-
dard subsequent antineoplastic therapies received first upon
study treatment discontinuation was abiraterone, which was
administered to 47.3% (61/129) and 50% (90/180) of
enzalutamide and placebo switchers, respectively.
Docetaxel was administered to 26.1% (228/872) of patients
in the enzalutamide arm and 47.5% (401/845) of patients in
the placebo arm as the first antineoplastic therapy after study
drug discontinuation (Table 3). Given that docetaxel is part of
the standard treatment pathway in the UK, these patients were
classified as nonswitchers in our analysis.
The mean (median) time from study drug discontinuation
to the start of first antineoplastic treatment was 2.15 (1.28)
months for the overall population, with similar distributions
in the enzalutamide arm and placebo arm [1.98 (1.25) vs. 2.28
(1.28) months, respectively].
There were potentially important differences in the demo-
graphic characteristics of switchers and nonswitchers. Higher
proportions of switchers than nonswitchers were asymptom-
atic at baseline [69.2% (211/305) vs. 62.5% (606/970), respec-
tively] and had an Eastern Cooperative Oncology Group
Performance Status of 0 at the last assessment before treat-
ment discontinuation [58.9% (182/309) vs. 38.7% (380/981),
respectively], while higher proportions of nonswitchers than
switchers experienced grade 3 or greater adverse events at the
last assessment before treatment discontinuation [27.9% (274/
Table 2 Patient disposition and
switcher counts (intention-to-treat
population)
Patient disposition Enzalutamide
(n = 872)
Placebo
(n = 845)
Total
(N = 1717)
Patients who died 241 (27.6) 299 (35.4) 540 (31.5)
Patients who died after receiving
postbaseline antineoplastic therapy
38 (15.8) 46 (15.4) 84 (15.6)
Patients censored 631 (72.4) 546 (64.6) 1177 (68.5)
Patients who discontinued treatment 504 (57.8) 783 (92.7) 1287 (75.0)
Patients who did not discontinue treatment 367 (42.1) 61 (7.2) 428 (24.9)
Patients who did not receive study medication 1 (0.1) 1 (0.1) 2 (0.1)
Switchers 129 (14.8) 180 (21.3) 309 (18.0)
Data are presented in the table as the number of patients, with the percentages these numbers represent given in
parentheses, based on the number of patients in the intention-to-treat population, with the exception of
patients who died after receiving postbaseline antineoplastic therapy where the percentage is calculated from
the number of patients who died
Table 3 First postbaseline
antineoplastic treatment received
(intention-to-treat population)
Treatment Enzalutamide (n = 872) Placebo (n = 845) Total (N = 1717)
Nonswitchers (n = 981)
Docetaxel 228 (26.1) 401 (47.5) 629 (36.6)
Hormonal 11 (1.3) 16 (1.9) 27 (1.6)
Antiandrogen 14 (1.6) 45 (5.3) 59 (3.4)
Switchers (n = 309)a
Enzalutamide 1 (0.1) 0 (0.0) 1 (0.1)
Abiraterone 61 (7.0) 90 (10.7) 151 (8.8)
Cabazitaxel 14 (1.6) 22 (2.6) 36 (2.1)
Sipuleucel-T 10 (1.1) 9 (1.1) 19 (1.1)
Investigational 28 (3.2) 43 (5.1) 71 (4.1)
Other chemotherapy: cytotoxic 14 (1.6) 14 (1.7) 28 (1.6)
Other chemotherapy: noncytotoxic 1 (0.1) 2 (0.2) 3 (0.2)
Data are presented in the table as the number of patients, with the percentages these numbers represent given in
parentheses, based on the number of patients in the intention-to-treat population
a Treatments listed for ‘Switchers’ in this table are considered NOT to be part of the standard treatment pathway in
the UK
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981) vs. 14.6% (45/309), respectively] or at any time prior to
this [41.4% (406/981) vs. 25.2% (78/309), respectively].
3.2 Overall Survival
3.2.1 Unadjusted ITT Analysis
The results of an unadjusted ITT analysis suggested that
enzalutamide extended OS relative to placebo (HR 0.71;
95% CI 0.60–0.84).
3.2.2 Two-Stage Method
For the two-stage method, AFs were calculated by fitting gen-
eralized gamma and Weibull models to the observational
datasets (Table 4). The AIC and BIC statistics suggested that
the generalized gammamodel would be a better fit for the data
than theWeibull model, and thus the generalized gammamod-
el was selected as the model of choice. AFs of >1.0 indicated
that switchers experienced extended survival compared with
nonswitchers in both the enzalutamide and placebo groups.
The generalized gamma model suggested that this benefit
was slightly greater in the placebo group.
Adjusted HRs for OS for the two-stage method are shown
in Table 4, together with the median times to event. Kaplan–
Meier curves (Fig. 2) showed that a substantial amount of
information was lost with recensoring of the data, creating
the potential for considerable bias under the assumption that
the treatment effect changed over time. Thus, the preferred
two-stage approach was considered to be one that used a gen-
eralized gamma model and did not incorporate recensoring.
This yielded an adjusted HR for OS of 0.66 (95% CI 0.57–
0.81) for enzalutamide versus placebo (Table 5).
More detailed information relating to these results, includ-
ing information pertaining to sensitivity analyses, is provided
in ESM 1.
3.2.3 IPCW Method
Adjusting for treatment switching of 14.8% and 21.3% in
enzalutamide and placebo patients, respectively, the IPCW
resulted in a HR for OS of 0.63 (95% CI 0.52–0.75) versus
placebo (Table 4). Weighted Kaplan–Meier curves are shown
in Fig. 3. Stabilized weights were utilized and, therefore, the
IPCW HR was adjusted for baseline covariates. However, the
weighted Kaplan–Meier curves shown in Fig. 3 were not ad-
justed for baseline covariates.
An exploration of the distribution of the stabilized weights
was performed (see ESM 7), which showed that for both treat-
ment arms and all follow-up intervals the mean was very close
to 1. For enzalutamide, the smallest and largest weight was
0.91 and 2.21, respectively, which is comparable to 0.96 and
3.25, respectively, for placebo. More detailed information,
including data pertaining to sensitivity analyses, is provided
in ESM 1, 7 and 8.
3.3 Updated OS Analysis
A subsequent analysis was performed, in line with the FDA
request to analyze the OS endpoint with a minimum of the
original protocol-defined number of deaths (756), at a data
cutoff of June 1, 2014. At this time point, 784 deaths had
occurred, with 99.9% (844/845) of placebo-treated patients
and 73.3% (639/872) of enzalutamide-treated patients having
discontinued treatment. (As previously mentioned, one patient
in each treatment group had not received study medication.)
There were 416 switchers, representing 19.7% (172/872) and
28.9% (244/845) of patients in the enzalutamide and placebo
arms, respectively. The HR for OS for enzalutamide versus
placebo was 0.77 (95% CI 0.67–0.88) in the ITT analysis,
compared with 0.74 (95% CI 0.64–0.86) in the two-stage
method (generalized gamma without recensoring) and 0.66
(95% CI 0.57–0.77) in the IPCW analysis.
4 Discussion
The original results from the PREVAIL study demonstrated an
OS benefit with enzalutamide for the treatment of mCRPC in
chemotherapy-naïve patients [10]. That analysis, performed
after 540 reported deaths, showed evidence of a significant
29% reduction in the risk of death for patients originally
Table 4 Acceleration factors
calculated by fitting the Weibull
and generalized gammamodels to
the observational datasets in the
PREVAIL trial (two-stage
method)
Parametric model Treatment arm Acceleration factor (95% CI)a Diagnostic criteria
AIC BIC
Weibull Enzalutamide 1.76 (1.24–2.49) 1087.36 1176.12
Placebo 1.30 (0.96–1.76) 1469.01 1566.96
Generalized gamma Enzalutamide 1.13 (0.83–1.54) 868.20 961.19
Placebo 1.35 (0.99–1.85) 1468.78 1571.40
AIC Akaike information criterion, BIC Bayesian information criterion, CI confidence interval
a An acceleration factor of >1.0 indicates a treatment benefit associated with switching
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randomized to enzalutamide versus placebo (HR 0.71; 95%
CI 0.60–0.84) [10]. However, for an analysis of the treatment
benefit that would be expected if enzalutamide was to be in-
corporated into the treatment pathway in the UK, it is neces-
sary to adjust for any treatments received during the
PREVAIL trial that are outside the standard UK treatment
pathway (other than the enzalutamide received in the
experimental arm of the study). The original results from the
PREVAIL study used standard ITT methodology, which may
inaccurately estimate the true OS benefit associated with an
original investigational product when switching to another
active treatment subsequently occurs [2], as is frequently the
case in oncology trials if cancer progresses. Consequently, in
an attempt to provide a better estimate of the effect of
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enzalutamide on OS in a UK-specific context, adjustments for
switching to active postprogression antineoplastic therapies
that were not part of the standard UK treatment pathway were
made using the observational-based two-stage [5, 6] and
IPCW [6] methods. Both methods resulted in a numerical
reduction in the HR compared with the unadjusted analysis,
producing values of 0.66 (95% CI 0.57–0.81) and 0.63 (95%
CI 0.52–0.75), respectively, suggestive of a slightly larger
effect of enzalutamide on OS compared with the interim anal-
ysis (HR 0.71; 95% CI 0.60–0.84) [10]. Thus, by adjusting for
switching to nonstandard antineoplastic therapies in 14.8%
(129/872) of enzalutamide- and 21.3% (180/845) of
placebo-treated patients, enzalutamide was shown to be asso-
ciated with an approximately 34% reduction in mortality risk
with the two-stage method and a decrease of approximately
37% using the IPCWanalysis.
A subsequent OS analysis, performed at a data cutoff asso-
ciated with 784 deaths, also showed that the adjustment
methods produced numerical reductions in the HR compared
with the ITT analysis for OS for enzalutamide versus placebo
at this time point. Given the potential importance of reductions
in the HR for clinical and reimbursement decision-making, it
Table 5 Overall survival analysis: unadjusted and adjusted results
Analysis Treatment No. patients with events Median (95% CI) time to
event (months)
HR (95% CI)
Unadjusted ITT Enzalutamide 241 32.36 (30.09–NYR) 0.71 (0.60–0.84)
Placebo 299 30.19 (27.96–NYR)
Two-stage method
Gamma AF without recensoringa Enzalutamide 241 32.36 (30.09–NYR) 0.66 (0.57–0.81)
Placebo 299 28.71 (26.87–NYR)
Gamma AF with recensoring Enzalutamide 198 NYR 0.62 (0.47–0.81)
Placebo 216 NYR
Weibull AF without recensoring Enzalutamide 241 31.47 (30.09–NYR) 0.69 (0.58–0.83)
Placebo 299 30.00 (26.87–NYR)
Weibull AF with recensoring Enzalutamide 106 NYR 0.65 (0.45–0.80)
Placebo 222 NYR
IPCW method 0.63 (0.52–0.75)
a Preferred approach for two-stage method
AFAcceleration factor, CI confidence interval,HR hazard ratio, IPCW inverse probability of censoring weights, ITT intention to treat, NYR not yet reached
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is appropriate to consider our methodological choices in more
detail.
After discontinuation of the study drug, patients in both
arms of the PREVAIL trial switched to several different treat-
ments. Randomization-based methodologies, such as the
RPSFTM or IPE algorithm, were not considered to be suitable
for adjustment, as they are typically unable to adequately ac-
count for switching when patients may receive a variety of
poststudy active therapies; these methods are appropriate
when switching is directly from the comparator treatment to
the randomized treatment [2]. Although a multiparameter
RPSFTM may be considered to model more complex
switching scenarios, in practice, such methodology has been
shown to be unhelpful [16–20].
Having assessed the pivotal assumptions underlying the
available adjustment methods, and taking into account the
characteristics of the PREVAIL study [10] and treatment
switching mechanism, we regarded the observational-based
two-stage method as applicable to the PREVAIL data.
However, this method required an appropriate secondary
baseline and, with the PREVAIL study not specifying any
particular point (time or event, such as disease progression)
at which switching could occur, and no actual switching date
available for nonswitchers, the treatment discontinuation date
was used. This is a potential weakness of the analysis, as it
relies on the assumption that the secondary baseline represents
a similar disease-related time point for all patients. This is
more obviously the case when the secondary baseline is the
time of disease progression than when it is the time of treat-
ment discontinuation. Nevertheless, with patients originally
randomized to both enzalutamide and placebo having
switched treatment, and the primary reason for discontinuing
study drug being disease progression, the treatment discontin-
uation date may be considered to represent an adequate
disease-related time point for an appropriate secondary base-
line. A large number of variables potentially prognostic for
survival and capable of enabling accurate adjustment for dif-
ferences between switchers and nonswitchers had been
assessed in the study up to this time point and were available
for use as covariates in the two-stage analysis. Therefore, it
was considered appropriate to assume that the no unmeasured
confounders assumption was approximately true.
The two-stage adjustment method can be applied in a num-
ber of different ways, such as (1) with and without recensoring
and (2) using different accelerated failure time models to esti-
mate the effect of switching. Our preferred approach was to
use the generalized gamma model without recensoring. The
practice of recensoring is generally recommended for ap-
proaches that estimate counterfactual survival times as it re-
duces bias by breaking the dependence between censoring
time and treatment [16]. However, recensoring was consid-
ered inappropriate in the current study as this led to the loss
of a substantial amount of long-term information, creating the
potential for considerable bias if the treatment effect changes
over time. In the Kaplan–Meier analyses (Fig. 2b), the
enzalutamide curve showed little change after adjustment,
whereas a slight worsening of survival was apparent for the
placebo group. The magnitude of such changes was in line
with expectations, given the low proportions of switchers
(14.8 and 21.3% of patients in the enzalutamide and placebo
groups, respectively) and the fact that adjustment has been
made for a treatment effect likely to be relatively small—al-
though the AF was >1.0, indicating a treatment benefit asso-
ciated with switching, it was neither substantially greater than
this nor statistically significant.
The IPCW method was also considered to be suitable for
this post-hoc analysis of PREVAIL data because a large num-
ber of covariates likely to be prognostic for survival and with
the potential to predict an investigator’s decision to switch a
patient’s treatment were collected in the trial. Therefore, we
could reasonably assume that the no unmeasured confounders
assumption was plausible. This adjustment method involves
censoring when patients switch to other treatments and may
thus be prone to bias if this proportion is very high. However,
this was not the case in PREVAIL where there were relatively
low proportions of switchers. Therefore, the IPCW, acknowl-
edged as a valid option to correct for switching bias [21–23],
was considered to be appropriate. When applying the IPCW
method it is important to explore the distributions of the
weights. In some instances a poor performing covariate will
cause many extreme weights, and extreme weights can cause
the resultant analysis to be prone to error. An exploration of
the distribution of stabilized weights showed that the mean
was very close to 1.0 for both treatments and all follow-up
intervals, with no extreme weights observed.
An important limitation associated with the IPCW as ap-
plied to PREVAIL was that no covariate data were collected
after treatment discontinuation in the trial. Therefore, time-
dependent confounding could occur between the time of treat-
ment discontinuation and the time of treatment switch. This
negates one of the important theoretical advantages that the
IPCW holds over the two-stage method—in theory, the IPCW
adjusts for any patient characteristic differences that occur
between the time point of the secondary baseline and the time
of treatment switch, whereas the two-stage method does not.
However, given the data collected in PREVAIL, both adjust-
ment methods were prone to this confounding. In relation to
this, it is relevant to note that the interval between the second-
ary baseline and the time of switch was not substantial and
was similar between the enzalutamide and placebo arms
[mean 1.98 (median 1.25) vs. mean 2.28 (median 1.28)
months, respectively] and could have been a consequence of
logistical delays in the administration of new antineoplastic
treatment.
Another limitation, applicable to both the two-stage and
IPCW methods, was reliance on a key assumption of there
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being no unmeasured confounders. Although this assumption
could not be tested in practice, the methods were likely to have
performed acceptably if it was approximately true, such that
any important independent predictive variables were taken
into account [2]. With the list of covariates being based on
clinical expert opinion and prior knowledge from the litera-
ture, and a considerable volume of data having being collected
in PREVAIL, the assumption of no unmeasured confounders
may be regarded as reasonable in this instance.
The two-stage method predicted that the switching effect
(in terms of improved survival after switching to nonstandard
active treatments) was greater in the placebo group of
switchers than in the enzalutamide group of switchers. It is
possible that this could have been a consequence of cross-
resistance [24, 25] affecting enzalutamide-treated patients
switching to abiraterone, which was the most common of
the nonstandard subsequent first antineoplastic therapies.
Further information on potential cross-resistances would be
valuable.
5 Conclusion
Overall, in line with the original analysis from the PREVAIL
study [10], our adjusted analyses demonstrated the OS benefit
of enzalutamide versus placebo for men with chemotherapy-
naïve mCRPC. Both adjustment methods produced similar
results, which increases confidence that they have performed
appropriately and produced credible results, with HR sugges-
tive of a slightly higher treatment effect than apparent with the
original ITT analysis. This result is important for interpreting
the results of the trial both from a clinical and a cost-
effectiveness point of view. Although these analyses have
been undertaken from a UK treatment pathway perspective,
such adjustment methods may also be relevant for economic
analyses in other countries, being tailored to take into account
the treatment pathways in the countries under consideration.
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